Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group.

@article{Beart1990AdjuvantTF,
  title={Adjuvant therapy for resectable colorectal carcinoma with fluorouracil administered by portal vein infusion. A study of the Mayo Clinic and the North Central Cancer Treatment Group.},
  author={Robert W. Beart and Charles G. Moertel and Harry S. Wieand and Janet E. Leigh and Harold E. Windschitl and Jon A. van Heerden and Robert Joseph Fitzgibbons and Bruce G. Wolff},
  journal={Archives of surgery},
  year={1990},
  volume={125 7},
  pages={897-901}
}
We randomized 224 patients with resected Dukes' stage B2 or C colorectal cancer to either an untreated control group or to a group receiving 7 days of fluorouracil therapy (500 mg/m2 per day) by portal vein infusion. Randomization was accomplished during surgery after staging by frozen section. Only 5 (2.2%) of our 224 patients were ineligible, but an additional 10 patients assigned to portal vein infusion could not be treated because of technical problems with catheter placement. Toxic… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 20 extracted citations

Similar Papers

Loading similar papers…